

## LABORATORY REPORT

Name : **NESRINE DJEBBARA** File. No. : **AAL02-428552**  
DOB/Gender : **16-11-2001 (23 Yrs 4 Month /Female)** Referral Doctor : **Dr. Amaizah Ishtiaq**  
Lab No. : **22250750143** Referral Clinic : **Citicare Medical Center LLC**  
Request Date : **16-03-2025 14:11:11** Clinic File No : **45101**  
Insurance : **NATIONAL GENERAL INSURANCE (HEALTHNET)**

## HAEMATOLOGY & COAGULATION

| Test Name                                                  | Result                  | Units               | Ref. Range   | Method                               |
|------------------------------------------------------------|-------------------------|---------------------|--------------|--------------------------------------|
| <b><u>COMPLETE BLOOD COUNT (CBC) WITH DIFFERENTIAL</u></b> |                         |                     |              |                                      |
| <b>RBC</b>                                                 | 4.63                    | 10 <sup>12</sup> /L | 3.80 - 4.80  | Hydrodynamic focusing (DC Detection) |
| <b>Haemoglobin</b>                                         | 12.1                    | g/dl                | 12.0 - 15.0  | Photometry-SLS                       |
| <b>HCT</b>                                                 | 36.1                    | %                   | 36.0 - 46.0  | Hydrodynamic focusing (HF)           |
| <b>MCV</b>                                                 | <b>78.0<sup>L</sup></b> | fl                  | 83.0 - 101.0 | Calculation                          |
| <b>MCH</b>                                                 | <b>26.1<sup>L</sup></b> | pg                  | 27-32        | Calculation                          |
| <b>MCHC</b>                                                | 33.5                    | g/dL                | 31.5 - 34.5  | Calculation                          |
| <b>Platelet Count</b>                                      | 308                     | 10 <sup>3</sup> /uL | 150-400      | HF (DCD)                             |
| <b>WBC</b>                                                 | 7.92                    | 10 <sup>3</sup> /uL | 4.00 - 10.00 | Flow Cytometry                       |
| <b><u>DIFFERENTIAL COUNT (%)</u></b>                       |                         |                     |              |                                      |
| <b>Neutrophils</b>                                         | 51.4                    | %                   | 40.0 - 80.0  | Flow Cytometry                       |
| <b>Lymphocytes</b>                                         | 32.8                    | %                   | 20.0 - 40.0  | Flow Cytometry                       |
| <b>Monocytes</b>                                           | <b>11.7<sup>H</sup></b> | %                   | 2-10         | Flow Cytometry                       |
| <b>Eosinophils</b>                                         | 3.7                     | %                   | 1 - 6        | Flow Cytometry                       |
| <b>Basophils</b>                                           | 0.4                     | %                   | <1-2         | Flow Cytometry                       |
| <b>Band Forms</b>                                          | 0.0                     | %                   | < 6          | Flow Cytometry                       |
| <b><u>DIFFERENTIAL COUNT (ABSOLUTE)</u></b>                |                         |                     |              |                                      |
| <b>Neutrophils (Absolute)</b>                              | 4.07                    | 10 <sup>3</sup> /uL | 2.00 - 7.00  | Calculation                          |
| <b>Lymphocytes (Absolute)</b>                              | 2.60                    | 10 <sup>3</sup> /uL | 1.00 - 3.00  | Calculation                          |
| <b>Monocytes (Absolute)</b>                                | 0.93                    | 10 <sup>3</sup> /uL | 0.20 - 1.00  | Calculation                          |
| <b>Eosinophils (Absolute)</b>                              | 0.29                    | 10 <sup>3</sup> /uL | 0.02 - 0.50  | Calculation                          |
| <b>Basophils (Absolute)</b>                                | 0.03                    | 10 <sup>3</sup> /uL | 0.02 - 0.10  | Calculation                          |
| <b>Band Forms (Absolute)</b>                               | 0.00                    | 10 <sup>3</sup> /uL | < 0.66       | Calculation                          |

### Remarks:

Recommended to do peripheral smear, iron studies and thalassemia screening.  
Test result to be interpreted in the light of clinical history and to be investigated further if necessary.

These tests are accredited under ISO 15189:2022 unless specified by (\*)

Sample processed on the same day of receipt unless specified otherwise.

Test results pertain only the sample tested and to be correlated with clinical history.

Reference range related to Age/Gender.

**Dr. Solmaz Siddiqui**  
Laboratory Director  
DHA/LS/248469

Patient Sample Collected On : 16-03-2025 13:35:00  
Authenticated On : 16-03-2025 17:34:52

Received On : 16-03-2025 14:42:00  
Released On : 16-03-2025 17:48:34



**Rhea Suberon**  
Medical Laboratory Technician  
DHA-P-0123639



**LABORATORY REPORT**

|              |                                          |                 |                               |
|--------------|------------------------------------------|-----------------|-------------------------------|
| Name         | : NESRINE DJEBBARA                       | File. No.       | : AAL02-428552                |
| DOB/Gender   | : 16-11-2001 (23 Yrs 4 Month /Female)    | Referral Doctor | : Dr. Amaizah Ishtiaq         |
| Lab No.      | : 22250750143                            | Referral Clinic | : Citicare Medical Center LLC |
| Request Date | : 16-03-2025 14:11:11                    | Clinic File No  | : 45101                       |
| Insurance    | : NATIONAL GENERAL INSURANCE (HEALTHNET) |                 |                               |

| Test Name | Result | Units | Ref. Range | Method |
|-----------|--------|-------|------------|--------|
|-----------|--------|-------|------------|--------|

Sample Type : EDTA WB

These tests are accredited under ISO 15189:2022 unless specified by (\*)

Sample processed on the same day of receipt unless specified otherwise.

Test results pertain only the sample tested and to be correlated with clinical history.

Reference range related to Age/Gender.

**Dr. Solmaz Siddiqui**  
Laboratory Director  
DHA/LS/248469

Patient Sample Collected On : 16-03-2025 13:35:00  
Authenticated On : 16-03-2025 17:34:52

Received On : 16-03-2025 14:42:00  
Released On : 16-03-2025 17:48:34



**Rhea Suberon**  
Medical Laboratory  
Technician  
DHA-P-0123639

### LABORATORY REPORT

|              |                                          |                 |                               |
|--------------|------------------------------------------|-----------------|-------------------------------|
| Name         | : NESRINE DJEBBARA                       | File. No.       | : AAL02-428552                |
| DOB/Gender   | : 16-11-2001 (23 Yrs 4 Month /Female)    | Referral Doctor | : Dr. Amaizah Ishtiaq         |
| Lab No.      | : 22250750143                            | Referral Clinic | : Citicare Medical Center LLC |
| Request Date | : 16-03-2025 14:11:11                    | Clinic File No  | : 45101                       |
| Insurance    | : NATIONAL GENERAL INSURANCE (HEALTHNET) |                 |                               |

### CLINICAL BIOCHEMISTRY

| Test Name                       | Result | Units | Ref. Range             | Method                    |
|---------------------------------|--------|-------|------------------------|---------------------------|
| <b>C-Reactive Protein (CRP)</b> | 4.26   | mg/L  | Negative < or = to 5.0 | Immunoturbidimetric Assay |

CRP is an acute phase protein whose concentration rises non-specifically in response to inflammation. CRP values should not be interpreted without a complete clinical evaluation. Follow-up testing of patients with elevated values is recommended in order to help rule out a recent response to undetected infection or tissue injury. Please note Reference Range Reviewed w.ef 15/10/23

Sample Type : Serum

These tests are accredited under ISO 15189:2022 unless specified by (\*)

Sample processed on the same day of receipt unless specified otherwise.

Test results pertain only the sample tested and to be correlated with clinical history.

Reference range related to Age/Gender.

**Dr. Solmaz Siddiqui**  
Laboratory Director  
DHA/LS/248469

Patient Sample Collected On : 16-03-2025 13:35:00  
Authenticated On : 16-03-2025 17:34:52

Received On : 16-03-2025 14:42:00  
Released On : 16-03-2025 17:48:34



**Rhea Suberon**  
Medical Laboratory Technician  
DHA-P-0123639

**LABORATORY REPORT**

Name : **NESRINE DJEBBARA** File. No. : **AAL02-428552**  
DOB/Gender : **16-11-2001 (23 Yrs 4 Month /Female)** Referral Doctor : **Dr. Amaizah Ishtiaq**  
Lab No. : **22250750143** Referral Clinic : **Citicare Medical Center LLC**  
Request Date : **16-03-2025 14:11:11** Clinic File No : **45101**  
Insurance : **NATIONAL GENERAL INSURANCE (HEALTHNET)**

**LIPID PROFILE I  
CLINICAL BIOCHEMISTRY**

| Test Name                                          | Result                    | Units | Ref. Range                                                                                                              | Method                               |
|----------------------------------------------------|---------------------------|-------|-------------------------------------------------------------------------------------------------------------------------|--------------------------------------|
| <b>Cholesterol</b>                                 | 198.00                    | mg/dL | Desirable: < 200<br>Borderline: 200 - 239<br>High: >or =240                                                             | Enzymatic-Cholesterol esterase       |
| Please note Reference Range Reviewed w.ef 15/10/23 |                           |       |                                                                                                                         |                                      |
| <b>Triglycerides</b>                               | <b>244.00<sup>H</sup></b> | mg/dL | NCEP Adult Treatment Panel<br>Normal: <150<br>Borderline: 150 - 199<br>High: 200-499<br>Very High: >or =500             | Enzymatic GPO                        |
| Please note Reference Range Reviewed w.ef 15/10/23 |                           |       |                                                                                                                         |                                      |
| <b>HDL Cholesterol</b>                             | <b>37.90<sup>L</sup></b>  | mg/dL | Major Risk: < 40                                                                                                        | Homogeneous enzymatic-CHER & CHOD    |
| Please note Reference Range Reviewed w.ef 15/10/23 |                           |       |                                                                                                                         |                                      |
| <b>LDL Cholesterol</b>                             | <b>133.00<sup>H</sup></b> | mg/dL | Optimal: < 100<br>Near or above optimal: 100-129<br>Borderline High: 130 - 159<br>High: 160 - 189<br>Very High: >or=190 | Homo. Enz, Liq. Selective Surfactant |
| Please note Reference Range Reviewed w.ef 15/10/23 |                           |       |                                                                                                                         |                                      |
| <b>*Cholesterol / HDL</b>                          | <b>5.22<sup>H</sup></b>   | Ratio | Desirable: < 4.5<br>Borderline: 4.5 - 6<br>Undesirable: >6                                                              | Calculation                          |

**Remarks:**

Test result to be interpreted in the light of clinical history and to be investigated further if necessary.

Sample Type : Serum

----- End Of Report -----

These tests are accredited under ISO 15189:2022 unless specified by (\*)

Sample processed on the same day of receipt unless specified otherwise.

Test results pertain only the sample tested and to be correlated with clinical history.

Reference range related to Age/Gender.

**Dr. Solmaz Siddiqui**  
Laboratory Director  
DHA/LS/248469

Patient Sample Collected On : 16-03-2025 13:35:00  
Authenticated On : 16-03-2025 17:34:52

Received On : 16-03-2025 14:42:00  
Released On : 16-03-2025 17:48:34



**Rhea Suberon**  
Medical Laboratory Technician  
DHA-P-0123639